DE69928820D1 - Akt zusammensetzungen zur steigerung des überlebens von kardiomyozyten - Google Patents
Akt zusammensetzungen zur steigerung des überlebens von kardiomyozytenInfo
- Publication number
- DE69928820D1 DE69928820D1 DE69928820T DE69928820T DE69928820D1 DE 69928820 D1 DE69928820 D1 DE 69928820D1 DE 69928820 T DE69928820 T DE 69928820T DE 69928820 T DE69928820 T DE 69928820T DE 69928820 D1 DE69928820 D1 DE 69928820D1
- Authority
- DE
- Germany
- Prior art keywords
- cardiomyocytes
- survival
- increase
- compositions
- act
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title 1
- 230000004083 survival effect Effects 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5061—Muscle cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5064—Endothelial cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2510/00—Detection of programmed cell death, i.e. apoptosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- General Engineering & Computer Science (AREA)
- Cardiology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10274098P | 1998-10-02 | 1998-10-02 | |
PCT/US1999/022633 WO2000020025A2 (en) | 1998-10-02 | 1999-09-29 | Akt compositions for enhancing survival of cells |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69928820D1 true DE69928820D1 (de) | 2006-01-12 |
Family
ID=22291457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69928820T Expired - Lifetime DE69928820D1 (de) | 1998-10-02 | 1999-09-29 | Akt zusammensetzungen zur steigerung des überlebens von kardiomyozyten |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1117426B1 (de) |
JP (1) | JP2002528390A (de) |
AU (1) | AU772731B2 (de) |
CA (1) | CA2335391A1 (de) |
DE (1) | DE69928820D1 (de) |
WO (1) | WO2000020025A2 (de) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ514305A (en) | 1999-04-16 | 2004-01-30 | Univ Yale | eNOS mutations useful for gene therapy and therapeutic screening |
NZ519087A (en) * | 1999-11-23 | 2004-11-26 | Regeneron Pharma | Methods of inhibiting atrophy or promoting hypertrophy |
US6689807B1 (en) * | 2000-06-08 | 2004-02-10 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | HMG CoA reductase inhibitors for promoting angiogenesis |
US20040235163A1 (en) * | 2001-08-22 | 2004-11-25 | Mitsuhiro Yokota | Myocardial cell apoptosis inhibitors |
US20060294604A1 (en) * | 2003-02-17 | 2006-12-28 | Fridman Jordan S | Model for studying the role of genes in tumor resistance to chemotherapy |
MXPA06005424A (es) | 2003-11-13 | 2007-01-25 | Univ Georgia Res Found | Metodos para caracterizar virus de enfermedad bursal infecciosa. |
WO2006023879A1 (en) * | 2004-08-20 | 2006-03-02 | Board Of Regents, The University Of Texas System | Screening of agents for activity against ischemic myocardial insults |
US20090214507A1 (en) * | 2004-08-20 | 2009-08-27 | Regenerx Biopharmaceuticals, Inc. | Method of treating preventing, inhibiting or reducing damage to cardiac tissue |
US8137907B2 (en) | 2005-01-03 | 2012-03-20 | Cold Spring Harbor Laboratory | Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof |
CA2610265A1 (en) | 2005-05-31 | 2007-05-10 | Cold Spring Harbor Laboratory | Methods for producing micrornas |
BRPI0502497A (pt) * | 2005-06-28 | 2007-02-06 | Univ Minas Gerais | uso de agonistas e antagonistas do receptor acoplado a proteìna g, mas, como moduladores de atividade apoptótica para o estudo, a prevenção e o tratamento de doenças |
WO2007100722A2 (en) * | 2006-02-28 | 2007-09-07 | Trustees Of Boston University | Methods to identify factors associated with muscle growth and uses thereof |
US7862821B2 (en) | 2006-06-01 | 2011-01-04 | Merial Limited | Recombinant vaccine against bluetongue virus |
WO2009091992A1 (en) * | 2008-01-16 | 2009-07-23 | Purdue Research Foundation | Repairing damaged nervous system tissue with nanoparticles |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9100099D0 (sv) * | 1991-01-11 | 1991-01-11 | Kabi Pharmacia Ab | Use of growth factor |
WO1994025621A1 (en) * | 1993-04-30 | 1994-11-10 | Lxr Biotechnology Inc. | Methods of identifying potentially therapeutically effective agents and cell strains for use therein |
AU9774698A (en) * | 1997-09-09 | 1999-03-29 | Regents Of The University Of California, The | Inhibition of apoptotis using prosaposin receptor agonists |
-
1999
- 1999-09-29 CA CA002335391A patent/CA2335391A1/en not_active Abandoned
- 1999-09-29 DE DE69928820T patent/DE69928820D1/de not_active Expired - Lifetime
- 1999-09-29 WO PCT/US1999/022633 patent/WO2000020025A2/en active IP Right Grant
- 1999-09-29 AU AU62763/99A patent/AU772731B2/en not_active Ceased
- 1999-09-29 JP JP2000573384A patent/JP2002528390A/ja active Pending
- 1999-09-29 EP EP99950013A patent/EP1117426B1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CA2335391A1 (en) | 2000-04-13 |
AU772731B2 (en) | 2004-05-06 |
EP1117426B1 (de) | 2005-12-07 |
WO2000020025A3 (en) | 2000-07-06 |
JP2002528390A (ja) | 2002-09-03 |
EP1117426A2 (de) | 2001-07-25 |
AU6276399A (en) | 2000-04-26 |
WO2000020025A9 (en) | 2000-08-24 |
WO2000020025A2 (en) | 2000-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69920935D1 (de) | Vefahren zur verbesserung der süssefreigabe von sucralose | |
DE60029779D1 (de) | Zusammensetzungen zur Herstellung von En-Thiol-Elastomeren | |
CY2006003I2 (el) | Χρηση δαπτομυκινης | |
DE60238576D1 (de) | Zusammensetzung zur Herstellung von Elektroden und Elektroden | |
WO2001044271A3 (en) | Daptomycin analogs and their use as antibacterial agents | |
WO2001044272A3 (en) | Daptomycin analogs as antibacterial agents | |
DE69923500D1 (de) | Verfahren zur Herstellung von Fluorkautschukzusammensetzungen | |
DE69928820D1 (de) | Akt zusammensetzungen zur steigerung des überlebens von kardiomyozyten | |
DE69328072D1 (de) | Umweltfreundliche Zusammensetzungen zur Verbesserung des Viskositätsindexes | |
BG103914A (en) | Maintained separation of delayed gels | |
ATE401309T1 (de) | Verwendung von 2-fuoro-3-ketoestern zur herstellung von 3-fuoro-6,7,8,9-tetrahydro-4h- pyrimidoä1,2-aüpyrimidin-4-onen | |
EP1423122A4 (de) | Zusammensetzungen und verfahren in verbindung mit neuen benzodiazepin-verbindungen und ihre ziele | |
DE60100858D1 (de) | Prozess zur herstellung der kristallinen form i von cabergolin | |
DE60008830D1 (de) | Verfahren zur Herstellung von keramischen Zusammensetzungen | |
AU2002337388A1 (en) | Improvements in or relating to inhibition of viruses | |
ATE303153T1 (de) | Ibandroinsäure zur förderung der osseointegration der endoprothesen | |
DE60039965D1 (de) | Zusammensetzung zur erwerbung von immunologischer toleranz | |
IL155360A0 (en) | Processes for the isolation or purification of plavastatin and compositions containing plavastatin | |
DE69812438T2 (de) | Zusammensetzung zur herstellung von brennstoff-briketts | |
DE60022565T2 (de) | Verfahren zur Herstellung von Polyaminzusammensetzungen | |
DE69830156D1 (de) | Zusammensetzungen zur immunverstärkung von impfstoffen | |
GB9907516D0 (en) | Improvements relating to the application of adhesive | |
IT1304593B1 (it) | Composizione per combattere bio-organismi dannosi | |
GB0110097D0 (en) | Improvements in or relating to the protection of live fish | |
DE60004725D1 (de) | Verfahren zur Herstellung von Pigmentzusammensetzungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8332 | No legal effect for de |